Patient Start Form
PatientsHCPs
This site is for US Healthcare Professionals only.
Man contemplating the luck a penny will bring him.

A chance at relief isn’t luck. 
It’s ILARIS.

ILARIS is approved in five different indications within Periodic Fever Syndromes (PFS): FMF, HIDS/MKD, TRAPS, and CAPS (FCAS and MWS).1*

Not an actual patient. Individual results will vary. 

See how to identify PFS and what the indications look like

View PFS Criteria
Periodic Fever Syndromes Efficacy

In clinical trials, ILARIS was proven to help manage symptoms in patients with PFS

  • FMF
  • HIDS/MIKD
  • CAPS  (FCAS and MWS)
  • TRAPS
See Efficacy Data
Man leaving behind a lucky penny

Safety profile established across clinical trials 

Adverse events for FMF, HIDS/MKD, and TRAPS were studied in a different clinical trial than those of CAPS.1

See Safety Data

Explore the dosing schedule and administration instructions

See Dosage and Administration

Access & Support

Getting patients started
ILARIS Support Program
Getting Patients Started icon

Getting patients started

Access the Patient Start Form along with information about how to complete and submit it.

Click to Get Started
ILARIS Companion: Dedicated and dependable support

ILARIS Companion Program

View information about the patient support program and how to enroll to these services.

Learn More Here
*ILARIS is an FDA-approved treatment for adults and pediatric patients with Periodic Fever Syndromes (PFS): Familial Mediterranean Fever (FMF), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), Tumor Necrosis Factor Receptor–Associated Periodic Syndrome (TRAPS), and Cryopyrin-Associated Periodic Syndromes (CAPS) (ages 4 and older, including Familial Cold Auto-inflammatory Syndrome [FCAS] and Muckle-Wells Syndrome [MWS]).1

Reference: 1. Ilaris. Prescribing information. Novartis Pharmaceuticals Corp.